A citation-based method for searching scientific literature

Daisuke Shiraishi, Yukio Fujiwara, Yoshihiro Komohara, Hiroshi Mizuta, Motohiro Takeya. Biochem Biophys Res Commun 2012
Times Cited: 94



Tracey Gaspari, Iresha Welungoda, Robert E Widdop, Richard W Simpson, Anthony E Dear. Diab Vasc Dis Res 2013
Times Cited: 90




List of shared articles



Times cited

Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
Robyn Bruen, Seán Curley, Sarina Kajani, Gina Lynch, Marcella E O'Reilly, Eugène T Dillon, Eoin P Brennan, Mary Barry, Stephen Sheehan, Fiona C McGillicuddy,[...]. J Pharmacol Exp Ther 2019
15

Effect of GLP-1 based therapies on diabetic dyslipidemia.
Vishal J Patel, Amit A Joharapurkar, Gaurang B Shah, Mukul R Jain. Curr Diabetes Rev 2014
22


Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.
Robyn Bruen, Sean Curley, Sarina Kajani, Daniel Crean, Marcella E O'Reilly, Margaret B Lucitt, Catherine G Godson, Fiona C McGillicuddy, Orina Belton. Cardiovasc Diabetol 2017
31

A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
Yuko Tashiro, Kengo Sato, Takuya Watanabe, Kyoko Nohtomi, Michishige Terasaki, Masaharu Nagashima, Tsutomu Hirano. Peptides 2014
65

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.
Ángela Vinué, Jorge Navarro, Andrea Herrero-Cervera, Marta García-Cubas, Irene Andrés-Blasco, Sergio Martínez-Hervás, José T Real, Juan F Ascaso, Herminia González-Navarro. Diabetologia 2017
49

Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.
Tracey Gaspari, Melita Brdar, Huey Wen Lee, Iresha Spizzo, Yunshan Hu, Robert E Widdop, Richard W Simpson, Anthony E Dear. Diab Vasc Dis Res 2016
22


Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia.
María Aguilar-Ballester, Gema Hurtado-Genovés, Alida Taberner-Cortés, Andrea Herrero-Cervera, Sergio Martínez-Hervás, Herminia González-Navarro. Int J Mol Sci 2021
6